Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 816

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 816
---
 |     |                                                 | 237 |   |     |                              |  32.92 |

The following table summarizes stock options outstanding and exercisable under all plans at December 31, 2023:

|                  | Exercise price$ |     | NumberOutstanding atDecember 31, 2023(in thousands) |     |     | Weightedaverage remainingcontractual life(years) |     |     | Numberexercisable atDecember 31, 2023(in thousands) |
|:-----------------|:----------------|:----|----------------------------------------------------:|:----|:----|-------------------------------------------------:|:----|:----|----------------------------------------------------:|
| 4.66             |                 |     |                                                  79 |     |     |                                             9.67 |     |     |                                                   8 |
| 6.04             |                 |     |                                                   9 |     |     |                                             9.14 |     |     |                                                   — |
| 8.79             |                 |     |                                                  39 |     |     |                                             7.63 |     |     |                                                  16 |
| 12.75to16.25     |                 |     |                                                   6 |     |     |                                             8.78 |     |     |                                                   6 |
| 30.50to48.00     |                 |     |                                                  80 |     |     |                                             7.14 |     |     |                                                  47 |
| 62.00to68.50     |                 |     |                                                  14 |     |     |                                             6.81 |     |     |                                                  14 |
| 85.00            |                 |     |                                                   9 |     |     |                                             5.43 |     |     |                                                   9 |
| 304.95to2,660.00 |                 |     |                                                   1 |     |     |                                             2.33 |     |     |                                                   1 |
|                  |                 |     |                                                 237 |     |     |                                                  |     |     |                                                 101 |

<div align='center'>F-61</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

Stock options granted during the six months ended